[go: up one dir, main page]

MX2011012060A - Anticuerpos humanizados específicos de la forma protofibrilar del péptido beta-miloide. - Google Patents

Anticuerpos humanizados específicos de la forma protofibrilar del péptido beta-miloide.

Info

Publication number
MX2011012060A
MX2011012060A MX2011012060A MX2011012060A MX2011012060A MX 2011012060 A MX2011012060 A MX 2011012060A MX 2011012060 A MX2011012060 A MX 2011012060A MX 2011012060 A MX2011012060 A MX 2011012060A MX 2011012060 A MX2011012060 A MX 2011012060A
Authority
MX
Mexico
Prior art keywords
beta
humanized antibodies
antibodies specific
amyloid peptide
protofibrillar form
Prior art date
Application number
MX2011012060A
Other languages
English (en)
Inventor
Laurent Pradier
Francis Blanche
Vincent Mikol
Yi Shi
Nicolas Baurin
Beatrice Cameron
Marc Duchesne
Souad Naimi
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41591699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011012060(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2011012060A publication Critical patent/MX2011012060A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos humanizados específicos de la forma protofibrilar del péptido beta-amiloide, así como la utilización de estos anticuerpos en el ámbito de la enfermedad de Alzheimer.
MX2011012060A 2009-05-12 2010-05-11 Anticuerpos humanizados específicos de la forma protofibrilar del péptido beta-miloide. MX2011012060A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0953133A FR2945538B1 (fr) 2009-05-12 2009-05-12 Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
PCT/FR2010/050915 WO2010130946A1 (fr) 2009-05-12 2010-05-11 Anticorps humanises spécifiques de la forme protofibrillaire du peptide béta-amyloide

Publications (1)

Publication Number Publication Date
MX2011012060A true MX2011012060A (es) 2012-04-30

Family

ID=41591699

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012060A MX2011012060A (es) 2009-05-12 2010-05-11 Anticuerpos humanizados específicos de la forma protofibrilar del péptido beta-miloide.

Country Status (41)

Country Link
US (4) US8614299B2 (es)
EP (3) EP2977385B1 (es)
JP (2) JP2012526541A (es)
KR (1) KR101783058B1 (es)
CN (1) CN102459336B (es)
AR (1) AR076670A1 (es)
AU (1) AU2010247215B2 (es)
BR (1) BRPI1012853B1 (es)
CA (1) CA2761665A1 (es)
CL (1) CL2011002831A1 (es)
CO (1) CO6460745A2 (es)
CR (1) CR20110585A (es)
CY (2) CY1116842T1 (es)
DK (2) DK2430049T3 (es)
EA (1) EA028357B1 (es)
EC (1) ECSP11011452A (es)
ES (2) ES2542757T3 (es)
FR (1) FR2945538B1 (es)
GT (1) GT201100283A (es)
HR (3) HRP20150776T1 (es)
HU (1) HUE036737T2 (es)
IL (1) IL216237B (es)
LT (1) LT2977385T (es)
MA (1) MA33350B1 (es)
MX (1) MX2011012060A (es)
MY (1) MY159398A (es)
NI (1) NI201100195A (es)
NZ (1) NZ596540A (es)
PE (1) PE20120906A1 (es)
PL (2) PL2430049T3 (es)
PT (2) PT2977385T (es)
RS (1) RS54122B1 (es)
SG (1) SG176155A1 (es)
SI (2) SI2430049T1 (es)
SV (1) SV2011004058A (es)
TN (1) TN2011000571A1 (es)
TW (2) TWI583791B (es)
UA (1) UA107574C2 (es)
UY (1) UY32633A (es)
WO (1) WO2010130946A1 (es)
ZA (1) ZA201108301B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20171292T1 (hr) 2007-11-16 2017-12-15 The Rockfeller University Polipeptidi i konjugati klorotoksina i njihove uporabe
AR085302A1 (es) * 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
JP2013159596A (ja) * 2012-02-08 2013-08-19 Nihon Univ β−アミロイド前駆体タンパク質のマイクロ凝集体に特異的なモノクローナル抗体
MX359794B (es) 2013-03-15 2018-10-10 Intrinsic Lifesciences Llc Anticuerpos anti-hepcidina y usos de los mismos.
CA3090240A1 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
NZ730186A (en) 2014-09-22 2020-04-24 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
LT3280441T (lt) 2015-04-07 2021-11-25 Alector Llc Anti-sortilino antikūnai ir jų naudojimo būdai
EP3307771A2 (en) 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
WO2016201389A2 (en) 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
WO2017013599A1 (en) 2015-07-21 2017-01-26 Bioarctic Neuroscience Ab Method for treatment of traumatic brain injury targeting aggregated peptides
JP7525980B2 (ja) 2015-08-28 2024-07-31 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法
JP7725185B2 (ja) 2015-10-06 2025-08-19 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法
US10800844B2 (en) 2015-10-29 2020-10-13 Alector Llc Anti-Siglec-9 antibodies and methods of use thereof
JP7023853B2 (ja) 2016-03-04 2022-02-22 アレクトル エルエルシー 抗ｔｒｅｍ１抗体及びその使用方法
CN109996809A (zh) 2016-11-14 2019-07-09 诺华股份有限公司 与促融合蛋白minion相关的组合物、方法和治疗用途
EP3354278A1 (en) 2017-01-31 2018-08-01 Sanofi Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide
WO2018213316A1 (en) 2017-05-16 2018-11-22 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
PE20200148A1 (es) 2017-08-03 2020-01-17 Alector Llc Anticuerpos anti-trem2 y metodos para utilizarlos
CN117700548A (zh) 2017-08-03 2024-03-15 艾利妥 抗cd33抗体及其使用方法
CA3098710A1 (en) 2018-05-25 2019-11-28 Alector Llc Anti-sirpa antibodies and methods of use thereof
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
BR112020024919A2 (pt) 2018-06-08 2021-03-09 Alector Llc Anticorpos, ácido nucleico, vetor, célula hospedeira, métodos de produção de um anticorpo e de prevenção, redução do risco ou tratamento de câncer e composição farmacêutica
EP4212210A1 (en) 2018-07-13 2023-07-19 Alector LLC Anti-sortilin antibodies and methods of use thereof
WO2020023920A1 (en) 2018-07-27 2020-01-30 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
WO2020047374A1 (en) 2018-08-31 2020-03-05 Alector Llc Anti-cd33 antibodies and methods of use thereof
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
TW202110878A (zh) 2019-05-16 2021-03-16 法商賽諾菲公司 在神經系統中表現抗原結合蛋白
CR20210687A (es) 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
WO2021035033A1 (en) * 2019-08-20 2021-02-25 The Curators Of The University Of Missouri Amyloid-beta antibodies
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
AU2020403021A1 (en) 2019-12-12 2022-06-23 Alector Llc Methods of use of anti-CD33 antibodies
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
CN116157416A (zh) 2020-08-25 2023-05-23 吉利德科学公司 靶向hiv的多特异性抗原结合分子及其使用方法
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
AU2001291096A1 (en) * 2000-09-15 2002-03-26 Coley Pharmaceutical Gmbh Process for high throughput screening of CpG-based immuno-agonist/antagonist
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
WO2005087177A2 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
CA2544692C (en) * 2004-07-09 2014-04-01 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
KR20070040824A (ko) * 2004-07-30 2007-04-17 리나트 뉴로사이언스 코퍼레이션 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용방법
ATE497508T1 (de) * 2004-10-01 2011-02-15 Max Planck Gesellschaft Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
AU2006208226A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
WO2007108755A1 (en) * 2006-03-22 2007-09-27 Gyros Patent Ab Plex method
MY169492A (en) * 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
ES2439490T3 (es) * 2007-01-05 2014-01-23 University Of Zurich Anticuerpo anti-beta amiloide y usos del mismo
CN101675075B (zh) * 2007-03-01 2014-06-18 西福根有限公司 重组抗表皮生长因子受体抗体组合物
TR201807983T4 (tr) 2007-08-29 2018-06-21 Sanofi Sa İnsanlaştırılmış anti-CXCR5 antikorları, deriveleri ve kullanımları.
HRP20171292T1 (hr) * 2007-11-16 2017-12-15 The Rockfeller University Polipeptidi i konjugati klorotoksina i njihove uporabe
DK3211005T3 (da) * 2008-07-08 2021-06-07 Geneuro Sa Terapeutisk anvendelse af specifik ligand i msrv-associerede sygdomme
US8961991B2 (en) * 2009-03-10 2015-02-24 Baylor Research Institute Anti-CD40 targeted fusion proteins
CA2754764A1 (en) * 2009-03-10 2010-09-16 Baylor Research Institute Antigen presenting cell targeted cancer vaccines
TWI508976B (zh) * 2009-04-21 2015-11-21 Univ Rockefeller 對β－類澱粉蛋白之基原纖維形式具專一性之抗體

Also Published As

Publication number Publication date
AU2010247215B2 (en) 2015-08-20
EP2977385A1 (fr) 2016-01-27
IL216237A0 (en) 2012-01-31
HUE036737T2 (hu) 2018-07-30
US9382312B2 (en) 2016-07-05
CY1120413T1 (el) 2019-07-10
CN102459336A (zh) 2012-05-16
CY1116842T1 (el) 2017-03-15
RS54122B1 (sr) 2015-12-31
BRPI1012853A2 (pt) 2018-06-19
IL216237B (en) 2018-05-31
ES2664409T3 (es) 2018-04-19
MA33350B1 (fr) 2012-06-01
UY32633A (es) 2010-12-31
NZ596540A (en) 2013-05-31
JP2016028591A (ja) 2016-03-03
DK2977385T3 (en) 2018-04-16
EP3050898B1 (fr) 2018-08-15
EA201171388A1 (ru) 2012-05-30
US10112991B2 (en) 2018-10-30
KR101783058B1 (ko) 2017-09-28
TW201641690A (zh) 2016-12-01
TN2011000571A1 (fr) 2013-05-24
BRPI1012853B1 (pt) 2021-08-24
SI2977385T1 (en) 2018-05-31
EP2430049B1 (fr) 2015-04-15
SI2430049T1 (sl) 2015-08-31
US20190119365A1 (en) 2019-04-25
CA2761665A1 (fr) 2010-11-18
PL2430049T3 (pl) 2015-09-30
TW201100102A (en) 2011-01-01
TWI542360B (zh) 2016-07-21
US20160368977A1 (en) 2016-12-22
NI201100195A (es) 2012-02-01
GT201100283A (es) 2013-11-07
EP2977385B1 (fr) 2017-12-27
KR20120096950A (ko) 2012-08-31
US8614299B2 (en) 2013-12-24
AR076670A1 (es) 2011-06-29
JP6310895B2 (ja) 2018-04-11
TWI583791B (zh) 2017-05-21
PT2430049E (pt) 2015-09-01
US20140105890A1 (en) 2014-04-17
CO6460745A2 (es) 2012-06-15
MY159398A (en) 2016-12-30
ES2542757T3 (es) 2015-08-11
SV2011004058A (es) 2012-06-06
SG176155A1 (en) 2011-12-29
FR2945538A1 (fr) 2010-11-19
HK1167152A1 (en) 2012-11-23
HRP20150776T1 (hr) 2015-08-28
UA107574C2 (ru) 2015-01-26
EA028357B1 (ru) 2017-11-30
DK2430049T3 (en) 2015-07-20
EP3050898A1 (fr) 2016-08-03
PE20120906A1 (es) 2012-08-08
JP2012526541A (ja) 2012-11-01
CR20110585A (es) 2011-12-07
HRP20180516T1 (hr) 2018-05-04
CL2011002831A1 (es) 2012-05-11
HRP20181985T1 (hr) 2019-01-25
LT2977385T (lt) 2018-04-10
CN102459336B (zh) 2016-04-20
ECSP11011452A (es) 2011-12-30
AU2010247215A1 (en) 2011-12-15
WO2010130946A1 (fr) 2010-11-18
ZA201108301B (en) 2013-01-30
US20120177639A1 (en) 2012-07-12
EP2430049A1 (fr) 2012-03-21
FR2945538B1 (fr) 2014-12-26
PT2977385T (pt) 2018-04-03
PL2977385T3 (pl) 2018-06-29

Similar Documents

Publication Publication Date Title
MX2011012060A (es) Anticuerpos humanizados específicos de la forma protofibrilar del péptido beta-miloide.
MX2009011500A (es) Anticuerpos anti-mdl-1.
AU2018256498A1 (en) Antibodies to amyloid beta
MX2019014658A (es) Anticuerpos humanizados que reconocen la alfa-sinucleina.
IN2012DN01920A (es)
UA107600C2 (uk) АНТИТІЛО ПРОТИ N3pGlu БЕТА-АМІЛОЇДНОГО ПЕПТИДУ ТА ЙОГО ЗАСТОСУВАННЯ
MY171841A (en) Antibody formulation
MX2010004482A (es) Anticuerpos anti-proteina g vsr.
SG178886A1 (en) Humanized anti-cdcp1 antibodies
CA121760S (en) Bottle for cosmetics
ZA201304459B (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MY161868A (en) Anti-bv8 antibodies and uses thereof
WO2012021475A3 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
PH12013500143A1 (en) A method of treating alzheimer`s disease
NZ594347A (en) Antibodies against human tweak and uses thereof
PH12013500432A1 (en) Anti-vegfr-3 antibody compositions
GB0818080D0 (en) Immunogenic peptides
Hume Roger L’Estrange and the Making of Restoration Culture.
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions
EP2540742A4 (en) MONOCLONAL ANTIBODIES OF ANTI-CYR61 PROTEIN AND USES THEREOF

Legal Events

Date Code Title Description
FG Grant or registration